Kim Tae-Hee, Song Woo-Jin, Ryu Min-Ok, Kim Hyun-Tae, Nam Aryung, Youn Hwa-Young
Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University, Seoul 08826, Republic of Korea.
Laboratory of Veterinary Internal Medicine and Research Institute of Veterinary Medicine, College of Veterinary Medicine, Jeju National University, Jeju 63243, Republic of Korea.
Animals (Basel). 2024 Oct 17;14(20):2994. doi: 10.3390/ani14202994.
Lymphoma is one of the most common malignant tumors in dogs. Combination chemotherapy with vincristine, cyclophosphamide, doxorubicin, and prednisolone (CHOP) is the most effective treatment for multicentric lymphoma. Previous studies have evaluated the response of large dogs to CHOP treatment and identified prognostic factors; however, studies on small dogs are lacking. In this study, we investigated the outcomes and prognostic factors for small dogs with multicentric lymphoma treated with CHOP. The responses of patients to CHOP treatment were assessed, and 54.3% were evaluated as being in complete remission (CR), 31.4% in partial remission (PR), and 14.3% in no remission (NR). The overall response rate was 85.7%. The median survival times for CR, PR, and NR patients were 683 days (85-1496 days), 241 days (15-777 days), and 119 days (61-308 days), respectively. Among the CR patients, survival was longer under the following conditions: age under 10 years ( 0.011), no cardiovascular heart disease ( 0.046), and no history of hospitalization due to side effects from chemotherapy ( 0.002). These results might help clinicians build treatment plans for multicentric lymphoma in small breed dogs.
淋巴瘤是犬类最常见的恶性肿瘤之一。长春新碱、环磷酰胺、阿霉素和泼尼松龙联合化疗（CHOP）是多中心淋巴瘤最有效的治疗方法。先前的研究评估了大型犬对CHOP治疗的反应并确定了预后因素；然而，关于小型犬的研究却很缺乏。在本研究中，我们调查了接受CHOP治疗的小型多中心淋巴瘤犬的治疗结果和预后因素。评估了患者对CHOP治疗的反应，54.3%被评估为完全缓解（CR），31.4%为部分缓解（PR），14.3%为未缓解（NR）。总缓解率为85.7%。CR、PR和NR患者的中位生存时间分别为683天（85 - 1496天）、241天（15 - 777天）和119天（61 - 308天）。在CR患者中，在以下情况下生存时间更长：年龄小于10岁（P = 0.011）、无心血管疾病（P = 0.046）以及无化疗副作用导致的住院史（P = 0.002）。这些结果可能有助于临床医生为小型犬多中心淋巴瘤制定治疗方案。
